Relapsed/Refractory Myeloma: Navigating the Complex Treatment Landscape

In this podcast episode from Clinical Care Options, Paul G. Richardson, MD; Natalie S. Callander, MD; and Noopur Raje, MD, answer questions from a live webinar on therapeutic options currently available for patients with relapsed/refractory multiple myeloma. The topics covered include:How to sequence currently available therapies after relapseChallenges with using BCMA-targeted agents in clinical practiceExperts’ thoughts on the potential approval of bispecific agentsPresenters include:Paul G. Richardson, MDRJ Corman Professor of MedicineHarvard Medical SchoolClinical Program LeaderDirector of Clinical ResearchJerome Lipper Multiple Myeloma CenterDana Farber Cancer InstituteBoston, MassachusettsNatalie S. Callander, MDProfessor of MedicineSchool of Medicine and Public HealthUniversity of WisconsinDirectorMyeloma Clinical ProgramUniversity of Wisconsin Carbone Cancer CenterMadison, WisconsinNoopur Raje, MDDirectorCenter for Multiple MyelomaMassachusetts General Hospital Cancer CenterProfessor of MedicineHarvard Medical SchoolBoston, MassachusettsContent for this program was supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Karyopharm Therapeutics Inc.; and Regeneron Pharmaceuticals, Inc.Link to the full program, including downloadable slides and an on-demand webcast from the live event:https://bit.ly/3Fc7eMK

There are no comments yet.

Please log in to write the first comment.